Evaluation of product switching after a state Medicaid program began covering loratadine OTC 1 year after market availability

Journal of Managed Care Pharmacy

Volumn 12, Issue 2, 2006, Pages 108-120

  Trygstad, Troy K ^a   Hansen, Richard A ^a   Wegner, Steven E ^b,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b AccessCare of North Carolina ^*  (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Drug utilization; Loratadine; Low sedating antihistamine; LSA; Medicaid; OTC; Over the counter; Switching

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; DESLORATADINE; FEXOFENADINE; LORATADINE; NON PRESCRIPTION DRUG; DRUG DERIVATIVE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ARTICLE; CALCULATION; COMPARATIVE STUDY; CORRELATION ANALYSIS; DRUG CLASSIFICATION; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; HEALTH CARE POLICY; MEDICAID; PHARMACY; PRESCRIPTION; TIME SERIES ANALYSIS; UNITED STATES; DRUG USE; HEALTH INSURANCE; HUMAN; INSURANCE; ORGANIZATION AND MANAGEMENT; RETROSPECTIVE STUDY;

CETIRIZINE; DRUG UTILIZATION REVIEW; DRUGS, NON-PRESCRIPTION; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; LORATADINE; MEDICAID; NORTH CAROLINA; RETROSPECTIVE STUDIES;

EID: 33745488084     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.2.108     Document Type: Article

References (24)

1. Top 200 brand-name drugs by retail sales in 2001. Drug Top. Available at: http://www.drugtopics.com/drugtopics/article/ articleDetail.jsp? id=104555. Accessed November 21, 2005.
2. National Institute for Health Care Management Research and Educational Foundation. Prescription drug expenditures in 2001: another year of escalating drug costs. May 2002. Available at: http://www.nihcm.org. Accessed February 15, 2005.
3. U.S. Food and Drug Administration. CDER new and generic drug approvals: 1988-2004. Available at: http://www.fda.gov/cder/approval/index.htm. Accessed June 13, 2005. Also available at: http://www.fda.gov/cder/previous_news2002.htm. Accessed October 17, 2005.
4. Delate T, Henderson RR, Motheral BR. Financial impact of benefit design choice for non-sedating antihistamines. Express Scripts, Inc. Available at: https://www.express-scripts.com/ourcompany/news/outcomesresearch/ onlinepublications/studyfolder1. Accessed February 12, 2006.
5. Crowley JS, Ashner D, Elam L, for the Kaiser Commission of Medicaid and the Uninsured. Medicaid outpatient prescription drug benefits: findings from a national survey, 2003. Henry J. Kaiser Family Foundation; December 2003.
6. National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs, 2003. Reston, VA: National Pharmaceutical Council; 2004.
7. Sullivan PW, Nichol MB. The economic impact of payer policies after the Rx-to-OTC switch of low-sedating antihistamines. Value Health. 2004;7(4):402-12.
8. Sullivan PW, Follin SL, Nichol MB. Transitioning the low-sedating antihistamines to over-the-counter status: a cost-effectiveness analysis. Med Care. 2003;41(12):1382-95.
9. Zechnich AD, Greenlick M, Haxby D, Mullooly J. Elimination of over-the-counter medication coverage in the Oregon Medicaid population: the impact on program costs and drug use. Med Care. 1998;36(8):1283-94.
10. Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care. 2005;11(6):374-82.
11. Roper Starch Worldwide; 2001. Self-care in the new millennium: American attitudes toward maintaining personal health and treatment. Available at: http://www.chpa-info.org/web/press_room/statistics/PDFs/ CHPA_Final_Report_revised_03_20.pdf. Accessed December 7, 2005.
12. Soller RW. Evolution of self-care with over-the-counter medications. Clin Ther. 1998;20(suppl C):C134-C140.
13. Richards MK, Blumenfield S, Lyon RA. Managed care market perspectives on the over-the-counter availability of statins. J Manag Care Pharm. 2004;10(6):543-50.
14. RCS Express: an employee newsletter. August 2004; 6(1). Available at: http://www.richmond.k12.nc.us/august%202004.pdf. Accessed February 12, 2006.
15. Harris BN, West DS, Johnson J, et al. Effects on the cost and utilization of proton pump inhibitors from adding over-the counter omeprazole to drug benefit coverage in a state employee health plan. J Manag Care Pharm. 2004;10(5):449-55.
16. Dobson AL. Controlling pharmacy costs in the NC Medicaid program. NC Med Journal. 2003;64(6):280-82.
17. Cook TD, Campbell DT. Quasi Experimentation: Design and Analysis Issues for Field Settings. Boston: Houghton Mifflin; 1979.
18. Dormuth CR, Burnett S, Schneeweiss S. Using policy simulation to predict drug plan expenditure when planning reimbursement changes. Pharmacoeconomics. 2005;23(10):1021-30.
19. Silverman RA, Ito K, Stevenson L, Hastings HM. The relationship of fall school opening and emergency department asthma visits in a large metropolitan area. Arch Pediatr Adolesc Med. 2005;159(9):818-23.
20. North Carolina Division of Medical Assistance. General clinical policy statement: over the counter medications. September 1, 2004. Available at: http://www.dhhs.state.nc.us/dma/APA/A2.pdf. Accessed December 7, 2005.
21. National Pharmaceutical Council. Pharmaceutical Benefits Under State Medical Assistance Programs, 2004. Reston, VA: National Pharmaceutical Council; 2005.
22. Motheral B, Fairman K. Effect of a 3-tier prescription copay on pharmaceutical and other medical utilization. Med Care. 2001;39:1293-1304.
23. Kelsey JL, Whittemore AS, Evans AS, Thompson WD. Methods in observations epidemiology. 2nd ed. New York: Oxford University Press; 1996:34.
24. Lakomski PG, Chitre M. Evaluation of the utilization patterns of leukotriene modifiers in a large managed care health plan. J Manag Care Pharm. 2004;10(2):115-21.